AMRI makes a promotion in Singapore

Takeshi Yura becomes senior director of drug discovery services

Takeshi Yura has been promoted to senior director of drug discovery services at AMRI’s Singapore subsidiary.

In this expanded role, Yura will take overall responsibility for site management, which includes leadership of the AMRI Singapore Research Centre's chemistry, biology and r&d operations.

Yura will replace Raymond Yeung, who has been managing director of the site from 2007.

Initially joining the Singapore subsidiary in January as assistant director of medicinal chemistry, Yura has more than 22 years of experience in discovery chemistry, project management and business development.

Prior to joining AMRI, he was a director at Dishman Japan, responsible for sales and business development activities. Before this he was discovery chemistry research head at Pfizer Japan, and section head of medicinal chemistry at Bayer Yakuhin.

‘Since joining us earlier this year, we have been impressed with the extent of scientific and business leadership Dr Yura has brought to AMRI and look forward to the additional contributions he will bring to the company in this new role,’ said Bruce Sargent, senior vp of drug discovery at AMRI.

You may also like

Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
Ingredients

Meet Navetta: new approach to safety testing of drugs and particles

Turn inhalation research upside down
Subscribe now